SELLAS Life Sciences Group, Inc. Stock News

-  Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis – -  REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - -  Company to Host Webcast Call Today at 9:00 am ET NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceu...

- Median Overall Survival (mOS) Not Yet Reached, Now Exceeds 7.7. Months at Latest Follow-Up in the 30 mg BIW Cohort in Patients Relapsed or Refractory to Venetoclax-Based Regimens -

- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers –

– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 –

FRIEDBERG, Germany--(BUSINESS WIRE)--voxeljet AG (OTCMKTS: VJTTY) (the ‘Company', ‘voxeljet', or ‘we'), a provider of high-speed, large-format 3D printers and on-demand parts services to industrial and commercial customers, Dressler Group GmbH, and Fraunhofer IPA today announced the successful completion of a material study for waste PA12 powder from laser-based 3D printing systems. In the stud...

- Presentation at ASH will Feature Results from the Phase 2a Trial of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia After Venetoclax Failure –

- GPS Currently Investigated in Phase 3 REGAL Trial in Adult AML Patients – Interim Analysis Anticipated in Q4 2024 - - RPDD Provides Eligibility for GPS to Receive a Priority Review Voucher (PRV) Upon Marketing Approval that can be Transferred/Sold to Other Parties – - Recent Valuations for PRVs Remain Attractive (~$100 million/each) – NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sc...

NEW YORK, Oct. 10, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside chat at the 2024 Ma...